0      0

2022 AABB Virtual Annual Meeting

AM22-43-O - AM22-43-O: (On-Demand) Blood Safety: Epidemiological Surveillance and Risk Assessment for Emerging Pathogens (Enduring)

Nov 7, 2022 5:00pm ‐ Nov 7, 2022 6:00pm

Credits: None available.


Emerging infectious diseases (EIDs) can threaten blood safety and are a chief concern for blood operators. For novel EIDs, their transmissibility through transfusion may not be documented. This challenge may be compounded by the unavailability of diagnostic tests, in which case donor selection would be an alternative to safeguard against transmission. Therefore, to ensure blood safety, blood operators need a surveillance, modelling-based system that assesses risks. This session, presented by the Surveillance, Risk Assessment and Policy subgroup of the ISBT Working Party on Transfusion-Transmitted Infectious Diseases, will describe: • The organization of national and international cooperation on epidemiological surveillance in blood operators to identify EIDs worldwide, including mitigation strategies, risk analysis, and decision guidelines.
• A process for identifying and risk assessing EIDs to guide blood-safety-related decisions: lessons from the United Kingdom.

Learning Objectives:
  • Discuss the epidemiological surveillance strategies to identify emerging infectious diseases that might threaten blood safety worlwide
  • Describe mitigation strategies based on mathematical modelling to ensure blood safety
  • Review the undertaking, implementation, and impact of risk assessment on donor selection criteria to ensure blood safety
  • Discuss lessons learned from the United Kingdom experience




  • Claire Reynolds, BSc, MPhil : Nothing to Disclose
  • Steven Drews, PhD FCCM D(ABMM) : Johnson & Johnson (Janssen): Consultant Abbott: Grant/Research Support (Secondary Investigators need not disclose) Roche: Honoraria
  • Antoine Lewin, MD : Nothing to Disclose


Credits: None available.

You must be logged in and own this session in order to post comments.